BioSpace News Archive

Business

Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue guidance.

May 8, 2024
·
12 min read
Business

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.

May 8, 2024
·
18 min read
Business

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2024.

May 8, 2024
·
9 min read
Business

STERIS Announces Financial Results for Fiscal 2024 Fourth Quarter and Full Year

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 fourth quarter ended March 31, 2024.

May 8, 2024
·
17 min read
Next Generation Bioprinting Market Expected to Grow at a CAGR of 29.82 % From 2024 to 2031

Global Next Generation Bioprinting Market is projected to record a CAGR of 29.82 % during the forecast period of 2024-2031.

May 8, 2024
·
4 min read
Pharm Country

Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hotel, Miami Beach, Florida.

May 8, 2024
·
1 min read
Lone Star Bio

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced new data from a study further confirming the performance of its DecisionDx-UM test as a robust independent predictor of metastasis-free survival in patients diagnosed with UM.

May 8, 2024
·
9 min read
Business

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024.

May 8, 2024
·
14 min read
Deals

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Inhibrx, Inc. announced that it has set a record date of May 17, 2024 for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc., to holders of shares of the Company’s common stock on a pro rata basis.

May 8, 2024
·
12 min read
Business

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ: EPRX) (TSX: EPRX) today announced its financial results for the first quarter of 2024 and provided a corporate update.

May 8, 2024
·
12 min read